



ODYSSEY
HEALTH

ODYSSEY HEALTH, Inc.
Developing Life-Saving Medical Products

OTC: ODYY




Existing Product Portfolio



Pharmaceuticals

- **PRV-002**
Novel compound for treatment of concussion which currently has no FDA approved drug
- **PRV-001**
Novel compound intended to treat Niemann-Pick disease; potential Orphan Drug designation



Medical Devices

- **CardioMap**
Heart monitoring and screening device for early detection of coronary artery disease
- **Save-A-Life**
handheld choking rescue device



PRV-002

Novel Compound for Treatment
of Concussion

About Concussion

Concussions, represent a significant unmet medical need

- > **5 Million** per year in the US, 69M worldwide
- Medical costs in the US is **\$20 Billion per year in US**, \$400B worldwide

Current standard of care is rest, analgesics for headache, anti-depressants

Repeat concussions can lead to early dementia and Chronic Traumatic Encephalopathy

No FDA approved drug treatment exists for mTBI

75%

Likelihood of athlete head-injury recurrence

33%


Individuals over 65 that fall annually; 50% of deaths are from brain injury

25x

Frequency of military PTSD development post-concussion

About PRV-002

- New chemical entity: Proprietary Neurosteroid
- Proven in-vivo efficacy in animal concussion models through gene amplification of anti-inflammatories, anti-oxidants and efflux fluid channels
- Safety margin > 200-fold in animal toxicology studies
- Nasal administration drives drug into the brain in minutes
- IND-enabling studies complete
- Currently in a Phase 1 Human Clinical Trial
- Addressable market \$20B+ a year in the US alone





Mouth-to-Nose Administration

Intranasal (IN) administration allows rapid and direct accessibility to the brain

The Device

- requires patients to blow into the device which closes the soft palate eliminating the flow of drug to the lungs or esophagus
- Minimizes systemic exposure and side effects
- Enhances dispersion to the superior nasal roof for direct olfactory nerve brain delivery via a novel double tube airflow system
- Compact, 1X use lightweight-field deliverable




Superior depth of drug dispersion with double tube design

Early Development

Beyond Concussion, Odyssey

Plans to develop treatments of related brain injury and neuropsychiatric disorders with other novel neurosteroids (6) in its portfolio

- Major Depressive Disorder
- PTSD
- Dementia
- Generalized Anxiety
- Addiction
- ALS
- **Chronic Traumatic Encephalopathy (CTE)**



Scientific Advisory Board

James P. Kelly, MA, MD, FAAN, – Dr. Kelly is the Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, CO. He is National Director of the Gary Sinise Foundation Avalon Network TBI Medical Programs for which the MIBH serves as the clinical coordinating center. His immediate past position was Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center in Bethesda, MD.

Dallas C. Hack, MD, MPH, FACMPH, COL, US Army- COL(R) Hack served as the Command Surgeon for the US Army Central Command-Kuwait and the Deputy Commander for Clinical Services for 3rd MEDCOM during Operation Enduring Freedom in Iraq. Dr. Hack was the Director of the DoD's Combat Casualty Care Program, the premier research program for finding solutions for acute trauma in military settings. Currently, he serves as an Associate Clinical Professor, in the Department of Physical Medicine and Rehabilitation, School of Medicine, at Virginia Commonwealth University and an Adjunct Professor of Neurosurgery, at the School of Medicine, University of Pittsburgh. Dr. Hack is also a Brain Health Consultant working with the with NCAA, DoD and Cohen Veterans Bioscience.

Military Advisory Board

March 2022, Odyssey announced the formation of a Military Advisory Board

- **James “Jim” Linder** – Jim Linder: Major General USA (r) Former Chief of USSOCOM is a recognized leader in the world of Special Operations and Intelligence organizations as a high performing and skilled strategist.
- **Francis “Fran” Beaudette** – Fran Beaudette: Lieutenant General (r) had an illustrious 32-year career in the Army and Joint assignments, the majority of it as a Green Beret, he served with high performing organizations at varying levels, from a 12-man specials Special Forces ‘A-team’ to the 36,000- Soldier and Civilian US Army Special Operations Command.
- **Paul Toolan** – Paul Toolan: Lieutenant Colonel (r) Joined the Army as a Green Beret. Over the course of more than three decades in uniform, he has risen through the ranks and completed every elite school in the U.S Army.
- **Tim Szymanski** Commander of the Navy Seals (r)

The MAB will support Odyssey’s outreach efforts to the US Military regarding funding and clinical sites for our treatment for traumatic brain injuries

Sports Advisory Board

March 2021, Odyssey announced the formation of a Sports Advisory Board


- **Steve “Mooch” Mariucci** – Former NFL Head Coach, NFL’s Player Safety Advisory Committee; NFL “Head and Neck” Committee
- **Kurt Warner** – Son has a brain injury, passionate to find a treatment
- **Brett Favre** – NFL Hall of Fame Quarterback, Passion is to prevent/treat concussion especially in youth sports
- **Abby Wambach** – 2x Olympic gold medalist, World Cup Champion, suffered multiple concussions, passionate to find a cure.
- **Mark Rypien** – 2x Super Bowl Champion, Suffered severe post concussion syndrome, passionate to find a treatment.
- **David Ross** – Current Manager of the Chicago Cubs, 2x World Series Champion, Missed extended playing time to concussion, suffered post concussion syndrome, passionate to find a cure

The SAB will support Odyssey’s outreach efforts to **enhance public awareness** of traumatic brain injuries and concussion as well as **the need for an FDA approved therapy.**

PRV-002 SUMMARY

PRV-002 – a First-in-Class Novel Neurosteroid for the Treatment of Concussion

- IP covers composition of matter, methods of preparation and use
- No competing products currently available
- Pre-clinical efficacy established
- No drug-related toxicity observed
- Initial Formulation completed
- Unique Mouth to Nose applicator completed
- Phase I clinical trial underway
- Phase II clinical trials planned launch Fall 2022
- Potential for other neurological indications





CardioMap System

Heart Monitoring and Screening Device

Advantages of CardioMap



CardioMap requires less training to use and analyze than EKGs



CardioMap is more sensitive than EKG's; captures low-level electrical signals that EKG's don't pick up




CardioMap can generate a 3D dispersion map of the heart (see images)




Physicians using CardioMap can give patients actionable information about heart health years in advance


CardioMap™ Images (Dispersion Maps)



Healthy Heart



Moderately Diseased Heart



Severely Diseased Heart


CardioMap System



Small, portable device for early detection of heart disease **more effective than traditional imaging services**




Regulatory pathway via 510(k) – small study to show equivalence to legacy EKG



Highly profitable razor-razor blade model with recurring cloud-based service



Multiple end markets: Hospitals, Doctors' offices, Rehabilitation Centers, Sports Medicine Markets





Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical, anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions **in a matter of seconds without harm** to the victim

In development, not commercially available



Save-A-Life

Choking Rescue Device

In development, not commercially available

Board of Directors

J. Michael Redmond, Chairman, CEO

30 years experience leading Medical Device companies, commercialized several class II and Class III devices. He has leadership experience at public and private companies including Abbott Labs, and KMC Systems

John Gandolfo, Director

John has been CFO of several public and private medical device companies. He has raised over \$300M in IPOs and secondary offerings. John is Chair of the Audit Committee

Jerome (Jerry) Casey, Director

Jerry has 30 years experience leading commercial teams at Abbott Laboratories and recently as President of Genzyme Diagnostics (Sekesui)

Jeff Conroy, Director

Jeff is currently the Chairman and CEO of Embody Inc and brings over 30 years experience in the medical industry commercializing products and developing strategic alliances. Jeff has worked at Abbott Labs and Thermo Fisher

Ricky Richardson

Ricky has over 30 years of senior leadership experience in developing and manufacturing complex medical devices. Ricky has had senior leadership positions at Baxter and Danaher. He is a graduate of West Point.